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Abstract: Genetic variations in cell cycle checkpoints and DNA repair genes are associated 
with prolonged cell cycle G2 delay following ionizing radiation (IR) treatment and breast 
cancer risk. However, different studies reported conflicting results examining the association 
between post-IR cell cycle delay and breast cancer risk utilizing four different parameters: 
cell cycle G2 delay index, %G2–M, G2/G0–G1, and (G2/G0–G1)/S. Therefore, we evaluated 
whether different parameters may influence study results using a data set from 118 breast 
cancer cases and 225 controls as well as lymphoblastoid and breast cancer cell lines with dif-
ferent genetic defects. Our results suggest that cell cycle G2 delay index may serve as the best 
parameter in assessing breast cancer risk, genetic regulation of IR-sensitivity, and mutations 
of ataxia telangiectasia mutated (ATM) and TP53. Cell cycle delay in 21 lymphoblastoid cell 
lines derived from BRCA1 mutation carriers was not different from that in controls. We also 
showed that IR-induced DNA-damage signaling, as measured by phosphorylation of H2AX 
on serine 139 (γ-H2AX) was inversely associated with cell cycle G2 delay index. In summary, 
the cellular responses to IR are extremely complex; mutations or genetic variations in DNA 
damage signaling, cell cycle checkpoints, and DNA repair contribute to cell cycle G2 delay and 
breast cancer risk. The cell cycle G2 delay assay characterized in this study may help identify 
subpopulations with elevated risk of breast cancer or susceptibility to adverse effects in normal 
tissue following radiotherapy.
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Introduction
Breast cancer is the most common cancer among American women. In 2008, it is 
estimated that 182,460 new cases would be diagnosed and 40,480 women would die 
of breast cancer.1 Rare germ line mutations in DNA damage/repair response genes, 
such as BRCA1, BRCA2, ATM, FANC, and CHEK2, are associated with breast cancer 
susceptibility and highlight the importance of DNA damage/repair in breast cancer 
development.2 Prevalent low-penetrance polymorphisms in cell cycle checkpoint 
and DNA repair genes and their gene–gene and gene–environment interactions may 
underlie the etiology of breast cancer. Genetic variations in DNA damage signaling, 
cell cycle checkpoints, and DNA repair pathways may result in downregulation of 
damage signaling and repair functions which, when combined with environmental 
exposures, may result in genomic instability that promotes breast cancer. Accordingly, 
breast cancer risk may be associated with single nucleotide polymorphisms (SNPs) 
and mutations in cell cycle checkpoint and DNA repair genes, as well as overall 
cellular response to genotoxic insults, such as ionizing radiation (IR), the repair of Cancer Management and Research 2009:1 40
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which involves the combined action of multiple cell cycle 
checkpoints and DNA repair pathways.
Cellular exposure to IR induces a myriad of cytotoxic and 
premutagenic DNA damages, including double-strand breaks 
and oxidative DNA damage.3,4 Failure of cell cycle check-
point and repair pathways to correct DNA damages prior to 
replication may result in the propagation of deleterious chro-
mosomal aberrations and mutations that decrease genomic 
stability and lead to transformation. Therefore, assessment 
of defects in cell cycle checkpoints and DNA repair at the 
cellular level may allow for identification of individuals 
at high risk for breast cancer and afford opportunities for 
surveillance and behavioral intervention. IR sensitivity has 
been correlated with breast cancer risk.5–9 Methodologies 
for assessing IR sensitivity and breast cancer risk include 
genetic screening, comet assay, G2-irradiation chromo-
somal hypersensitivity assay (GICH), G2-micronucleus 
assay, and analysis of post-IR cell cycle arrest function in 
peripheral blood lymphocytes (PBLs).8,10–13 GICH and the 
G2-micronucleus assay, though effective at identifying IR 
sensitivity, are laborious and frequently utilize subjective 
analysis. The analysis of cell cycle G2 delay in PBLs fol-
lowing IR exposure has been used in numerous studies as 
a probe for genetic variations of cell cycle checkpoint and 
DNA repair genes that are associated with cancer risk.8,9,12,14 
Such assays are simple, inexpensive, and utilize automated 
sample analysis. However, sample size and the use of dif-
ferent methods for analysis of radiation-induced changes in 
cell cycle distribution, including G2 delay index, %G2–M, 
G2/G0–G1, and (G2/G0–G1)/S, may have contributed to con-
flicting results in population-based studies.5,8,15,16
We previously demonstrated an association between 
breast cancer risk and cell cycle G2 delay in a breast cancer 
case-control study.9 However, a recent study with smaller 
sample size found no association between breast cancer risk 
and IR sensitivity when cell cycle arrest was quantified using 
the parameter (G2/G0–G1)/S.15 Therefore, we first examined 
the IR sensitivity data from 118 breast cancer cases and 
225 controls reported in a previous study9 and compared 
the results obtained using four parameters described in 
previous studies: G2 delay index, %G2–M, G2/G0–G1, and 
%(G2/G0–G1)/S.5,8,15,16 Furthermore, we compared these four 
parameters in 54 lymphoblastoid and three breast cancer 
cell lines with different genetic defects in cell cycle check-
point and DNA repair. Lastly, we evaluated the association 
between phosphorylated histone H2AX, a measure of DNA 
damage signaling17 and cell cycle G2 delay index. This study 
aims to further characterize the cell cycle G2 delay assay as 
a simple and reproducible screening tool for assessing IR 
sensitivity and breast cancer risk.
Materials and methods
study population
Basal and IR-induced cell cycle distribution data in 
T lymphocytes were derived from a breast cancer-control 
study of 118 breast cancer cases and 225 controls as 
described previously.9 In brief, cancer-free women were 
recruited from the Comprehensive Breast Center and 
the Cancer Assessment and Risk Evaluation program at 
Georgetown University Medical Center from August 1995 to 
November 1996 as study controls. Breast cancer cases were 
recruited from the Breast Cancer Section of the Division 
of Hematology/Oncology. Each woman completed a self-
administered questionnaire requesting information about 
demographics, medical conditions, and family history (FH) 
of breast cancer in first-degree relatives. A woman with at 
least one first-degree relative with breast cancer was con-
sidered to have a positive FH. The general eligibility criteria 
were, (i) English-speaking and able to comprehend informed 
consent, (ii) no personal history of other cancers, and (iii) at 
least 18 years of age. Blood samples were taken from all 
study subjects. Subjects received a detailed description of the 
study protocol and signed informed consent as approved by 
the Institutional Review Board of the Georgetown University 
Medical Center.
Lymphoblastoid and breast cancer  
cell lines
Epstein–Barr virus-immortalized human lymphoblastoid 
cell lines from 21 BRCA1 mutation carriers, 12 controls, 
and 21 individuals from ATM families were obtained from 
the Coriell Institute for Medical Research (Camden, NJ). 
Lymphoblastoid cell lines were maintained in RPMI 1640, 
15% fetal bovine serum (FBS), at 37°C, 5% CO2. Human 
breast cancer cell lines MCF7, BT-20, and HCC1937 were 
obtained from American Type Culture Collection (Manassas, 
VA) and maintained in the recommended growth medium 
at 37°C, 5% CO2.
Mitogen response and cell cycle g2  
delay assay
The cell cycle distributions and IR-induced G2 delay data 
on 118 breast cancer cases and 225 controls were obtained 
from a previous study.9 In brief, PBLs were stimulated 
with phytohemagglutinin-P (PHA-P, Sigma-Aldrich, Cancer Management and Research 2009:1 41
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St Louis, MO) for 72 hours prior to irradiation. We reported 
the cell cycle G2 delay data but not the mitogen response 
data.9 In the current study, we performed the cell cycle delay 
assay in 54 lymphoblastoid and three breast cancer cell 
lines using the method as described previously with minor 
modifications.9 In brief, lymphoblastoid and breast cancer 
cell lines were plated 24 hours prior to irradiation at a cell 
concentration of 0.5 × 106/ml. Irradiation was performed 
using a Nordion Gammacell 137Cs irradiator at a dose rate 
of 0.9 Gy/min. Twenty-four hours post-irradiation, cells 
were harvested and stained with Vindelov’s propidium 
iodide (PI)18 containing 10 mM Tris-HCl, pH 8.0, 10 mM 
NaCl, 10 µg/mL RNase A, 0.1% NP-40 (Igepal CA-630; 
Sigma-Aldrich), and 75 µM PI. Untreated and IR-irradiated 
cells (3 Gy) were analyzed for cell cycle distribution (10,000 
cells per sample) using an LSR dual laser flow cytometer and 
CellQuest Pro software (BD BioSciences, San Jose, CA).
The cell cycle G2 delay index was calculated as (% irradiated 
cells in G2–M – % control cells in G2–M)/(% control cells in 
S phase) × 100.9 Other parameters were calculated as fol-
lows: %G2–M (% of irradiated cells in G2–M),16 G2/G0–G1 
(% irradiated cells in G2–M)/(% irradiated cells in G0–G1) × 
100,5 (G2/G0–G1)/S, (% irradiated cells in G2–M)/(% irradiated 
cells in G0–G1)/(% controls cells in S) × 100.15 For assay qual-
ity control, we performed repeat measures at least twice for 
54 lymphoblastoid cell lines until the coefficient of variation 
(CV) for batch-to-batch variation dropped to less than 30%. 
For a majority of the samples, the inter-assay CV was under 
10% (range 5%–27%). We also established that the intra-
individual variation in 23 lymphocyte samples with repeat 
visits was very low (mean CV at 6%).
Histone H2AX phosphorylation  
(γ-H2AX) assay
Lymphoblastoid cell lines in culture were centrifuged at 
300 × g for 10 min and resuspended in 4°C growth medium 
(RPMI 1640, 15% FBS, antibiotics) at a concentration of 
3.3 × 106 cells/ml. One hundred and fifty microliters (0.5 × 106 
cells) of cells was irradiated on ice for 10 min (9 Gy) at a dose 
rate of 0.9 Gy/min in a 137Cs irradiator. Following irradiation, 
cells were immediately placed in a 37°C water bath for repair. 
After repair for up to 4 hours, tubes were placed on ice and 
150 µl of cold medium containing 0.2% NP-40 was added 
to each tube. Tubes were inverted 10x and kept on ice in the 
dark for one hour to block nonspecific binding sites. 33 µL 
of a 1:200 solution of γ-H2AX-FITC antibody (16-202A; 
Millipore, Billerica, MA) in ice cold medium containing 0.1% 
NP-40 was added to each tube for a final 1:2000 antibody 
dilution. Tubes were mixed by inversion 10x and placed on ice 
for 1 hour in the dark. Cells were transferred to flow cytometry 
tubes and stained with 3.3 µl of PI (50 µg/mL). PI positive 
cells were analyzed for relative FITC staining (10,000 cells) 
using an LSR flow cytometer and fluorescence intensity was 
quantified using CellQuest Pro software.
statistical analysis
To compare cell cycle distribution in PHA-activated 
T lymphocytes and cell cycle delay in breast cancer cases 
and controls, a one-way ANOVA, stratified by breast cancer 
family history, was performed using SPSS software (version 
15.0; SPSS, Inc., Chicago, Illinois). We also performed 
Bonferroni post hoc pair wise comparisons. The means and 
standard deviations (SD) were presented. For quality control, 
CV (SD/mean) was calculated for intra-individual variations 
of repeat visits in 23 subjects and assay batch-to-batch varia-
tions of 54 lymphoblastoid cell lines.
Results
PHA response and iR sensitivity 
and breast cancer risk
In Table 1, the cellular response to PHA in PBLs from 118 
breast cancer cases was significantly lower compared to that 
in 225 controls based on the percentage of cells in S phase of 
the cell cycle (24.8% vs 28.5%; p  0.05). After 3 Gy of IR 
treatment, breast cancer cases have a significantly higher per-
centage of cells in G0–G1 phase (63.3% vs 59.0%, p  0.05) 
and lower percentage of cells in S phase (17.7% vs 21.2%; 
p  0.05). In Table 2, we used four different parameters 
for measuring IR-induced cell cycle delay: G2 delay index, 
%G2–M, G2/G0–G1, and (G2/G0–G1)/S. The G2 delay index 
was the only parameter that showed significant increases in 
IR-induced cell cycle delay in breast cancer cases compared 
to controls (36.0 vs 31.4; p  0.01). The other three param-
eters did not yield useful findings; the G2/G0–G1 ratio even 
showed a significantly lower value in breast cancer cases 
compared to controls (30.8 vs 34.7; p  0.05).
Cell cycle distribution and iR sensitivity 
in lymphoblastoid cell lines
In Table 3A, lymphoblastoid cell lines used in this study had 
similar cell cycle distributions without IR treatment. With IR 
treatment, cell lines from ATM mutation carriers, particularly 
five AT patients, had a lower percentage of cells in the G0–G1 
phase (38.7% vs 56.0%, Table 3B) or obligate ATM mutation 
carriers (38.7% vs 53.5%, Table 3B) and a higher percentage Cancer Management and Research 2009:1 42
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Table 1 Cell cycle distribution in breast cancer cases and controls
(A) Without IR treatment Control Case
Family history (N) % G0–G1 % S % G2–M (N) % G0–G1 % S % G2–M
none 87 60.7 ± 7.1 28.4 ± 5.7 10.9 ± 2.1 61 63.8 ± 6.8a 25.5 ± 5.7a 10.7 ± 2.4
Mother or sister 69 60.3 ± 5.8 29.0 ± 4.7 10.7 ± 1.9 11 65.9 ± 7.5a 24.1 ± 5.2a 10.0 ± 2.8
Mother and sister 13 60.6 ± 7.5 28.0 ± 5.7 11.4 ± 2.9 3 70.8 ± 4.4a 21.4 ± 5.9 7.8 ± 2.0
Missing 56 60.9 ± 4.8 28.0 ± 3.9 11.0 ± 1.9 43 66.0 ± 5.4a 24.1 ± 4.3a 9.8 ± 2.0a
Total 225 60.6 ± 6.2 28.5 ± 5.0 10.9 ± 2.1 118 64.9 ± 6.4a 24.8 ± 5.2a 10.3 ± 2.2a
(B) With IR treatment
none 87 59.1 ± 8.0 21.1 ± 5.6 19.8 ± 4.1 61 62.4 ± 7.0a 18.2 ± 5.3a 19.4 ± 3.3
Mother or sister 69 59.1 ± 7.9 21.4 ± 5.4 19.5 ± 4.2 11 62.9 ± 7.3 19.5 ± 4.4 17.5 ± 4.3
Mother and sister 13 57.0 ± 6.2 21.3 ± 5.5 21.7 ± 4.3 3 67.3 ± 2.6a 13.8 ± 2.2a 18.9 ± 2.6
Missing 56 59.3 ± 6.1 20.9 ± 4.3 19.8 ± 3.9 43 64.4 ± 6.3a 16.9 ± 4.3a 18.7 ± 3.4
Total 225 59.0 ± 7.4 21.2 ± 5.2 19.8 ± 4.1 118 63.3 ± 6.7a 17.7 ± 4.9a 19.0 ± 3.4
Notes: ap  0.05, pair-wise comparison, cases vs controls.
Abbreviation: iR, ionizing radiation.
of cells in the G2–M phase compared to controls (55.6% vs 
35.2%, Table 3B), BRCA mutation carriers (55.6% vs 37.0%, 
Table 3B), or obligate ATM mutation carriers (55.6% vs 
41.7%, Table 3B). In Table 4, the mean cell cycle delay 
following IR treatment in 21 heterozygous BRCA1 mutation 
carriers was not significantly different from that in controls 
using all four parameters. Although all four parameters 
were able to detect significantly higher cell cycle G2 delay 
in AT patients compared to each of the three other groups 
(p  0.05), only G2 delay index and (G2/G0–G1)/S detected 
significant higher cell cycle delay in obligate ATM mutation 
carriers (Table 4C) compared to controls (Table 4A) or cell 
lines with BRCA1 mutations (Table 4B).
Cell cycle distribution and iR sensitivity 
in breast cancer cell lines
Three breast cancer cell lines with different genetic 
backgrounds were evaluated for their response to IR. As 
shown in Table 5, without IR treatment, a higher percentage 
of cells from BT-20 and HCC1937 cell lines were present 
in the G2–M phase of the cell cycle compared to MCF7 cell 
line (31.9% and 32.1% vs 16.6%). Post-IR treatment, these 
two TP53-mutant lines, BT-20 and HCC1937, showed sig-
nificantly higher cell cycle delay compared to that of MCF7 
using all four parameters. The results suggest that TP53 muta-
tions may influence IR-induced cell cycle delay (Table 5). 
However, G2 delay index showed the maximal 20.7-fold dif-
ference in cell cycle delay between MCF7 and HCC1937 cell 
lines compared to 3.2-, 10.0-, and 8.9-fold differences using 
%G2–M, G2/G0–G1, and (G2/G0–G1)/S, respectively.
γ-H2AX induction in irradiated 
lymphoblastoid cell lines
H2AX phosphorylation kinetics differed significantly in 
irradiated lymphoblastoid cell lines from controls, obligate 
ATM mutation carriers, and AT patients (Figure 1). Control 
Table 2 ionizing radiation-induced cell cycle delay in breast cancer cases and controls
Family history (N) G2 delay index %G2–M G2/G0–G1 (G2/G0–G1)/S
  Control Case Control Case Control Case Control Case Control Case
none 87 61 31.6 ± 11.5 35.1 ± 12.8 19.8 ± 4.1 19.4 ± 3.3 34.7 ± 10.9 31.9 ± 7.9 1.21 ± 0.3 1.26 ± 0.2
Mother or sister 69 11 30.1 ± 10.7 31.8 ± 12.3 19.5 ± 4.2 17.5 ± 4.3 34.3 ± 10.7 29.0 ± 10.7 1.17 ± 0.3 1.18 ± 0.2
Mother and sister 13 3 38.3 ± 17.8 51.4 ± 12.3 21.7 ± 4.3 18.9 ± 2.6 38.8 ± 9.77 28.2 ± 4.7 1.40 ± 0.3 1.34 ± 0.2
Missing 56 43 30.9 ± 10.5 37.2 ± 13.4a 19.8 ± 3.9 18.7 ± 3.4 34.2 ± 9.72 29.8 ± 8.1a 1.22 ± 0.3 1.24 ± 0.3
Total 225 118 31.4 ± 11.5 36.0 ± 13.1a 19.8 ± 4.1 19.0 ± 3.4 34.7 ± 10.5 30.8 ± 8.2a 1.21 ± 0.3 1.25 ± 0.2
Notes: ap  0.001, pair-wise comparison, cases vs controls.Cancer Management and Research 2009:1 43
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cells had the most rapid and largest increase in γ-H2AX level 
following IR exposure. Cells from controls and obligate ATM 
mutation carriers reached maximal γ-H2AX induction within 
30 min post-irradiation. However, cells from AT patients had 
a slower and lower γ-H2AX induction (p  0.05 at 15, 30, and 
60 min) which peaked two hours after irradiation. γ-H2AX 
induction in cells from obligate ATM mutation carriers fol-
lowed kinetics similar to controls, but the maximum γ-H2AX 
induction level was intermediate between that observed in 
controls and AT patients. At four hours post-IR treatment, all 
three groups of cells showed similar levels of γ-H2AX.
Discussion
Using data derived from a relatively large breast cancer case-
control study and cell lines with different genetic defects, 
our current results support previous findings that prolonged 
cell cycle G2 delay in response to IR may serve as a sensitive 
biomarker for assessing IR sensitivity and breast cancer predis-
position. Some of the conflicting results in the literature may be 
related to: (1) study sample size and related statistical power, 
(2) PHA-induced PBLs vs lymphoblastoid cell lines, and (3) 
parameters used for interpreting the study results.5,9,15,16
Another interesting finding in this study is that response of 
PBLs to PHA is lower in breast cancer cases compared to that 
in controls. Several earlier studies reported that PBLs from 
cancer patients are less responsive to mitogenic stimulation by 
PHA and other plant lectins compared to healthy controls.19–20 
Our current data clearly demonstrate that PHA-stimulated 
PBLs from breast cancer cases had a significantly higher 
percentage of cells in the G0–G1 and a lower percentage of 
cells in the S phase compared to controls. PHA-induced 
proliferation of PBLs derived from patients with breast cancer 
may reflect tumor load and be a good clinical predictor for 
the further course of the disease.21 Antitumor T lymphocytes 
play a pivotal role in immune surveillance of cancer cells. 
Therefore, PHA-stimulated T lymphocyte cell cycle distribu-
tion may also serve as an immune function marker for cancer 
risk. Our observation is also consistent with the results from 
a recent study showing that genetic polymorphisms in cyto-
toxic T-lymphocyte antigen 4 influenced T-cell activation and 
modified the susceptibility to breast and other cancers.22
Breast cancer case-control differences in PBL response 
to PHA have an impact on studies of IR-induced cell cycle 
delay. Since only cycling cells are arrested in G2–M fol-
lowing irradiation, PBLs with lower percentages of cycling 
cells would produce a lower percentage of G2-arrested cells, 
subsequently influencing study results. Therefore, we intro-
duced the G2 delay index to normalize the results with the 
percentage of cells in S phase without IR treatment.8,9 The 
importance of adjusting for PHA response is clearly dem-
onstrated in Table 2, where significant prolonged cell cycle 
delay in breast cancer cases was observed only when G2 delay 
index was used. Neither %G2–M nor (G2/G0–G1)/S showed a 
case-control difference in cell cycle delay. When G2/G0–G1 
was used, we even observed a lower cell cycle delay response 
in breast cancer cases compared to that in controls.
PBLs and lymphoblastoid cell lines from BRCA1 and 
ATM mutation carriers have previously been analyzed for 
associations between IR-induced cell cycle delay and muta-
tion status.12,15,16,23 Mutations in BRCA1 or ATM are risk 
factors for breast and ovarian cancers.2,24 The results from 
recent studies suggest that BRCA1 plays critical roles in 
Table 3 Cell cycle distribution in lymphoblastoid cell lines
(A) Without IR treatment N %G0–G1 % Sa %G2–M
Controls 12 60.8 ± 6.3 29.6 ± 5.9b 9.6 ± 1.0
BRCA mutation carriers 21 60.1 ± 5.4 29.0 ± 4.9 10.8 ± 1.6
ATM mutation carriers 16 63.7 ± 5.2 24.8 ± 4.9 11.6 ± 5.0
AT patients 5 60.7 ± 2.9 26.5 ± 3.0 12.8 ± 0.9
(B) With IR treatment %G0–G1
a % Sa %G2–Ma
Controls 12 56.0 ± 6.3b 8.9 ± 1.8b,e 35.2 ± 5.9b
BRCA mutation carriers 21 55.9 ± 8.2c 7.1 ± 2.1f 37.0 ± 7.3c
ATM mutation carriers 16 53.5 ± 7.9d 4.8 ± 1.6 41.7 ± 7.0d
AT patients 5 38.7 ± 5.9 5.7 ± 0.3 55.6 ± 5.8
Notes: ap  0.05, AnOVA test for differences among four cell lines; bp  0.05, Bonferroni post hoc pair-wise comparison, cell lines from controls compared to AT patients; 
cp  0.05, Bonferroni post hoc pair-wise comparison, cell lines form BRCA1 mutation carriers compared to AT patients; dp  0.05, Bonferroni post hoc pair-wise comparison, 
cell lines from ATM mutation carriers compared to AT patients; ep  0.05, Bonferroni post hoc pair-wise comparison, cell lines from controls compared to ATM mutation 
carriers; fp  0.05, Bonferroni post hoc pair-wise comparison, cell lines from BRCA1 mutation carriers compared to ATM mutation carriers.
Abbreviation: iR, ionizing radiation.Cancer Management and Research 2009:1 44
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Table 4 ionizing radiation-induced cell cycle delay in lymphoblastoid cell lines
Repository G2 delay %G2–M G2/G1 (G2/G1)/S
(A) Controls (n = 12)
gM14807 100 ± 5 41 ± 5 81 ± 20 2.5 ± 0.3
gM14548 96 ± 15 37 ± 8 69 ± 24 2.4 ± 0.5
gM14453 95 ± 11 35 ± 7 64 ± 18 2.4 ± 0.5
gM01990 95 ± 11 34 ± 6 61 ± 19 2.3 ± 0.5
gM10924 88 ± 10 40 ± 5 81 ± 15 2.3 ± 0.2
gM14448 87 ± 16 39 ± 4 74 ± 16 2.2 ± 0.2
gM14476 85 ± 9 31 ± 8 53 ± 19 1.9 ± 0.4
gM14452 84 ± 16 40 ± 5 84 ± 20 2.4 ± 0.4
Ag09387 84 ± 11 43 ± 4 93 ± 14 2.4 ± 0.5
gM14673 83 ± 23 27 ± 11 47 ± 24 2.0 ± 0.5
gM01814 75 ± 15 31 ± 4 53 ± 11 1.8 ± 0.1
gM13079 72 ± 12 24 ± 5 36 ± 12 2.0 ± 0.5
Mean ± sD 87.0 ± 8.5a,b 35.2 ± 5.9b 66.2 ± 17.1b 2.2 ± 0.2a,b
(B) BRCA1 mutation carriers (n = 21)
gM13713 120 ± 17 45 ± 3 89 ± 13 3.3 ± 0.2
gM15993 116 ± 9 52 ± 7 135 ± 42 3.8 ± 0.8
gM14637 103 ± 10 35 ± 3 58 ± 8 2.3 ± 0.2
gM13715 100 ± 23 42 ± 5 86 ± 17 2.8 ± 0.8
gM13712 99 ± 6 45 ± 5 100 ± 21 3.2 ± 0.4
gM13714 97 ± 25 35 ± 6 64 ± 17 2.4 ± 0.6
gM13707 95 ± 15 40 ± 5 71 ± 15 2.5 ± 0.7
gM13710 95 ± 13 48 ± 6 112 ± 27 3.1 ± 0.6
gM14636 92 ± 15 34 ± 5 59 ± 13 2.1 ± 0.3
gM15232 90 ± 6 47 ± 5 113± 32 2.7 ± 0.4
gM14093 89 ± 15 32 ± 5 52 ± 14 2.0 ± 0.5
gM16105 89 ± 12 38 ± 7 72 ± 22 2.3 ± 0.5
gM14097 88 ± 18 34 ± 6 61 ± 17 2.2 ± 0.4
gM14638 88 ± 12 35 ± 6 63 ± 18 2.2 ± 0.3
gM14092 82 ± 9 34 ± 1 56 ± 3 1.9 ± 0.2
gM14094 80 ± 10 29 ± 8 45 ± 18 1.9 ± 0.3
gM14091 80 ± 9 27 ± 2 40 ± 5 2.1 ± 0.4
gM13705 78 ± 19 36 ± 6 68 ± 18 2.2 ± 0.5
gM14096 78 ± 9 36 ± 4 70 ± 15 2.0 ± 0.3
gM13709 71 ± 13 28 ± 4 43 ± 8 1.7 ± 0.3
gM14090 61 ± 10 25 ± 5 37 ± 10 1.6 ± 0.3
Mean ± sD 90.0 ± 13.9c,d 37.0 ± 7.3d 71.1 ± 26.2d 2.4 ± 0.6c,d
(C) ATM mutation obligate carriers (n =16)
gM09579 162 ± 32 49 ± 4 105 ± 16 4.4 ± 1.0
gM00736 160 ± 15 48 ± 12 106 ± 54 4.5 ± 1.6
gM02781 155 ± 20 32 ± 1 49 ± 2 3.5 ± 0.3
gM02782 134 ± 12 46 ± 25 129 ± 122 4.6 ± 2.3
gM09583 130 ± 23 45 ± 3 94 ± 12 3.4 ± 0.7
(Continued)Cancer Management and Research 2009:1 45
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DNA repair, recombination, checkpoint control of the cell 
cycle, transcription, and S- and G2-phase checkpoints in 
response to IR.25–27 We compared the IR-induced G2 delay in 
lymphoblastoid cell lines from controls and BRCA1 carriers 
using G2 delay index and three other parameters (Table 4). 
None of the methods could distinguish a difference in BRCA1 
heterozygote mutation carriers compared to controls. Our 
findings are consistent with a recent study that showed normal 
post-IR cell cycle kinetics in BRCA1 mutation carriers23 and 
suggest that one functional BRCA1 allele may be sufficient 
for its normal post-IR checkpoint function.
An association between mutations in the ATM gene and IR 
hypersensitivity has been demonstrated in numerous studies as 
summarized in a recent review.28 Early studies identified that 
AT cells are defective in immediate cell cycle checkpoints in 
response to IR, but a later ATM-independent response causes 
these irradiated cells to accumulate in G2 relative to normal 
cells.12,29 Therefore, we also evaluated the four parameters in 
lymphoblast cell lines derived from AT patients and obligate 
ATM mutation carriers. All four parameters showed signifi-
cantly higher cell cycle delay in cell from AT patients. In 
contrast to a previous study,15 we also showed significantly 
higher cell cycle delay in cells from obligate ATM mutation 
carriers compared to that in controls using G2 delay index and 
(G2/G0–G1)/S. The difference in study results may be related 
to a larger sample size of our study with 16 ATM mutation 
carriers and 12 controls compared to the previous study with 
four ATM mutation carriers and four controls.15
We further investigated the association between G2 delay 
index and IR-induced H2AX phosphorylation in seven 
lymphoblastoid cell lines (Figure 1). In response to DNA 
double-strand strand breaks induced by IR or other genotoxic 
agents, H2AX is rapidly phosphorylated at Ser-139 (γ-H2AX) 
by ATM and other kinases, including ATR and DNA PK.30 
γ-H2AX is immediately localized to DSB sites where it is 
believed to recruit additional factors required for comple-
tion of DNA repair.31 The formation and disappearance of 
γ-H2AX foci in a nucleus are proportional to the induction 
and repair of double-strand breaks, respectively.32 The result 
of DNA double-strand breaks measured by γ-H2AX levels 
is in agreement with data obtained using the comet assay.33 
Thus, the kinetics of γ-H2AX formation may be a useful 
surrogate for DNA double-strand break induction and repair. 
The established role of ATM kinase in post-IR double-strand 
Table 4 (Continued)
Repository G2 delay %G2–M G2/G1 (G2/G1)/S
gM03383 127 ± 11 39 ± 4 66 ± 13 2.8 ± 0.1
gM03188 125 ± 34 46 ± 5 97 ± 22 3.6 ± 1.7
gM09580 124 ± 16 47 ± 2 103 ± 11 3.3 ± 0.4
gM02783 122 ± 70 46 ± 7 105 ± 36 4.3 ± 0.9
gM03325 118 ± 10 48 ± 1 104 ± 4 3.2 ± 0.1
gM03187 116 ± 14 40 ± 1 71 ± 3 2.7 ± 0.3
gM03324 115 ± 16 40 ± 5 73 ± 17 2.8 ± 0.5
gM03323 107 ± 17 40 ± 3 75 ± 10 2.6 ± 0.4
gM03334 97 ± 12 30 ± 4 46 ± 10 2.2 ± 0.5
gM03333 84 ± 19 44 ± 9 90 ± 40 6.8 ± 5.6
gM03380 77 ± 16 26 ±1 37 ± 3 1.6 ± 0.4
Mean ± sD 122.1 ± 24.2e 41.7 ± 7.0e 84.4 ± 25.8e 3.5 ± 1.2e
(D) AT patients (n = 5)
gM09581 200 ± 10 61 ± 2 179 ± 7 7.7 ± 0.5
gM09582 164 ± 14 60 ± 0.2 173 ± 3 5.9 ± 0.4
gM00719 159 ± 27 59 ± 8 178 ± 66 5.9 ± 0.6
gM03332 148 ± 17 48 ± 23 136 ± 122 5.1 ± 2.9
gM03189 146 ± 30 50 ± 3 114 ± 9 4.6 ± 1.7
Mean ± sD 163.3 ± 21.9c 55.6 ± 5.8c 155.9 ± 29.4c 5.8 ± 1.2c
Notes: ap  0.05, controls vs ATM mutation carriers; bp  0.05, controls vs   AT patients; cp  0.05, BRCA1 vs ATM mutation carriers; dp  0.05, BRCA1 mutation carriers vs   AT 
patients; ep  0.05, ATM mutation carriers vs   AT patients.Cancer Management and Research 2009:1 46
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break repair and checkpoint function underlies the DNA 
repair deficient- and IR-sensitive phenotype observed in AT 
patients.34 Following IR exposure, cells from AT patients had 
slower and lower levels of γ-H2AX induction than those in 
obligate ATM carriers and controls (Figure 1). In addition to 
genetic variations in DNA repair, the results from the current 
study also demonstrate that defective DNA-damage signaling 
is associated with prolonged cell cycle G2 delay.
Analysis of IR-induced cell cycle delay in breast cancer 
cell lines utilizing the four parameters further supports the 
advantage of using the G2 delay index parameter. In three breast 
cancer cell lines, the G2 delay index was able to detect the larg-
est fold difference between the MCF7 and the HCC1937 cell 
lines (Table 5). Although both MCF7 and BT-20 cells express 
wild-type BRCA1,35 they exhibit very different IR responses. 
The difference may be related to TP53 mutation (AAG→
CAG; K132Q) in BT-20 cells36 since p53 plays critical role 
in checkpoint regulation.37 In HCC1937 cells, the presence of 
mutations in both BRCA1 (5382C) and TP53 (CGA→TGA; 
R306X)36 genes may contribute to its having the highest cell 
cycle delay among the three breast cancer cell lines.
In several studies, the association between IR sensitivity 
in patient PBLs and acute radiotherapy (RT) toxicity has been 
inconclusive.6,7,16,38 Some breast cancer patients experience RT-
induced acute adverse skin reactions of varying severity.39 In 
addition, RT-treated patients may also develop telangiectasia 
and fibrosis as late effects.40 Accordingly, there is increasing 
interest in the development of predictive tests for RT-induced 
adverse reactions. However, several studies have reported 
conflicting results utilizing chromosomal aberration analysis 
in predicting acute RT reactions.37,41,42 IR-induced DNA dam-
ages activate checkpoints that delay cell cycle progression to 
facilitate DNA repair. However, continued proliferation after 
DNA damage in IR-irradiated cells has been well documented. 
The results from a recent study estimated that cells with about 
10 to 20 double-strand breaks are released from a G2 check-
point delay and enter mitosis.43 Although these cells continue 
to divide for one to two cell cycles; the unrepaired damaged 
DNA eventually results in rapid apoptosis, senescence, a per-
manent cell cycle arrest, or mitotic catastrophe.44 Therefore, 
our validation of the cell cycle G2 delay assay suggests that 
it may serve as a simple screening tool to probe for com-
bined genetic defects and variations in cell cycle checkpoint 
regulation (eg, ATM and TP53 mutations) and DNA repair 
(eg, BRCA1 mutations and DNA repair SNPs) in assessing 
radio-sensitivity and cancer risk.
The major strengths of our study are: (1) large sample size 
of the case-control study and cell lines, (2) stringent laboratory 
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assay quality control with adequate batch-to-batch assay varia-
tions, (3) validation of the G2 delay index as the best parameter 
for testing IR sensitivity in a case-control study and among 
cell lines with different genetic defects, and (4) availability 
of genomic DNA for future testing of genotype–phenotype 
association studies. However, our study has several limita-
tions. First, the current study uses a dataset from a previous 
study. Future studies with a larger sample size and a different 
case-control population will be required to confirm our study 
findings and to evaluate the genetic regulation of cell cycle 
delay in IR sensitivity and breast cancer risk. Second, viable 
cells are required for performing the cell cycle assay, which 
may limit its application in population-based studies of breast-
cancer risk assessment and tumor response. Therefore, we are 
currently evaluating whether the newly developed antibody-
based γ-H2AX assay may overcome this limitation.
In summary, the cellular responses to IR-induced DNA 
damage are complex. The cell cycle G2 delay assay may 
serve as a probe for genetic defects/variations in cell cycle 
checkpoint regulation and DNA repair in assessing IR sen-
sitivity and breast cancer risk. However, there is a need to   
evaluate future genotype-phenotype relationships in cellular 
IR responses and compare results from other functional DNA 
damage and repair phenotype assays in order to establish the 
utility of the cell cycle G2 delay assay in the assessment of 
breast-cancer risk and prediction of RT response.
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